SINGAPORE-based biotech Cennerv Pharmaceuticals, a developer of drugs to treat central nervous system (CNS) disorders, lodged a preliminary prospectus on Wednesday for a planned initial public offering (IPO) on the Singapore Exchange's Catalist...
Register to read this article. Log in if you are already a subscriber.Register to read this article. Log in if you are already a subscriber.Please log in or subscribe to continue reading.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes